LENZ Therapeutics
PublicLENZ Therapeutics is now publicly traded
The data on this page reflects LENZ Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
PIPE
Jul 15, 2024
Total Funding Raised
$214M
Company Overview
LENZ Therapeutics (NAS: LENZ) is a biopharmaceutical company dedicated to developing and commercializing innovative therapies aimed at enhancing vision, with a primary focus on treating presbyopia, a common age-related decline in near vision affecting individuals over 45.
Sector
Healthcare
AI Layer
Non-AI
Keywords
LENZ Therapeutics Comparables
Compare LENZ Therapeutics with similar companies based on industry and business-model similarity.
No public comparables are available for LENZ Therapeutics. Request access to learn about comparables coverage.
Request accessLENZ Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Jul 15, 2024 | ||||
| PIPE | Mar 21, 2024 | ||||
| Series B | Mar 7, 2023 | ||||
| Series A | Jun 17, 2021 |
LENZ Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A, Series B, PIPE |
| Ridgeback Capital | PIPE |
| Versant Ventures | Series A, Series B, PIPE |
| Sectoral | Series B |
| RTW Investments | PIPE, Series B |
| Samsara BioCapital | PIPE |
| Alpha Wave Global | Series B, PIPE |
LENZ Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access